Healthcare (SH:603313)2019-03-29 16:00Financial Performance - The company's operating revenue for 2018 was approximately CNY 3.05 billion, representing a year-on-year increase of 30.39% compared to CNY 2.34 billion in 2017[24]. - The net profit attributable to shareholders of the listed company was approximately CNY 186.07 million, an increase of 19.39% from CNY 155.85 million in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 225.29 million, reflecting a significant increase of 73.29% compared to CNY 130.01 million in 2017[24]. - The net cash flow from operating activities reached approximately CNY 175.04 million, a substantial increase of 197.59% from CNY 58.82 million in the previous year[24]. - Basic earnings per share increased by 20.00% to CNY 0.78 in 2018 compared to CNY 0.65 in 2017[26]. - The weighted average return on equity rose by 1.48 percentage points to 11.38% in 2018 from 9.90% in 2017[26]. - The company reported a non-recurring loss of CNY 39,218,812.88 in 2018, compared to a gain of CNY 25,836,109.01 in 2017[31]. - The company achieved a 74.07% increase in basic earnings per share after deducting non-recurring gains and losses, reaching CNY 0.94 in 2018[26]. - The company reported a significant increase in cash flow from operating activities, amounting to ¥175,035,816.80, a 197.59% increase year-on-year[58]. Assets and Liabilities - The total assets of the company at the end of 2018 were approximately CNY 3.38 billion, marking a 46.22% increase from CNY 2.31 billion at the end of 2017[24]. - The net assets attributable to shareholders of the listed company were approximately CNY 1.85 billion, an increase of 21.11% from CNY 1.53 billion in 2017[24]. - The total assets at the beginning of the reporting period were RMB 2,308,676,862.42, and at the end of the period, total assets increased to RMB 3,375,853,349.34, resulting in an asset-liability ratio increase from 33.08% to 44.16%[160]. Market and Sales - The company’s main business focuses on developing and selling memory foam products, including mattresses and pillows, aimed at enhancing deep sleep[38]. - The company has established over 1,000 sales terminals in China and approximately 200,000 zero-pressure rooms, expanding its domestic market presence[46]. - The company’s overseas assets amount to 57,894.58 million RMB, accounting for 17.15% of total assets[48]. - The company’s overseas revenue grew by 31.67% year-on-year, while domestic revenue increased by 22.60%[65]. - The sales volume of memory foam mattresses reached 373.89 million units, an increase of 22.35% year-on-year[89]. - The company reported a total revenue of 13,134.06 million RMB from home product sales, with a year-over-year decline of 4.34%[101]. Research and Development - Research and development expenses increased by 10.88% to ¥88,848,871.30, reflecting the company's commitment to innovation[58]. - The total number of R&D personnel was 135, accounting for 10.19% of the company's total workforce[72]. - The company emphasizes employee training and development, launching over 100 courses under various programs to enhance employee skills and core competitiveness[198]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[6]. - The company has maintained a good integrity status during the reporting period, with no significant debts unpaid or commitments unfulfilled[134]. - The company has not faced any penalties from securities regulatory agencies in the past three years[194]. - The company adheres to strict governance practices, ensuring independent operation of the board and supervisory committee, with no incidents of fund misappropriation by controlling shareholders reported during the period[200]. Shareholder Information - The largest shareholder, Ni Zhanggen, holds 154,154,861 shares, representing 64.23% of the total shares, with 141,641,980 shares pledged[161]. - The total number of common shareholders at the end of the reporting period was 17,941, an increase from 16,752 at the end of the previous month[161]. - The company has no preferred shareholders with restored voting rights as of the reporting period[161]. - The company has a plan to increase shareholdings in accordance with the stock repurchase plan approved by the shareholders' meeting[128]. Future Plans and Strategies - The company plans to distribute a cash dividend of CNY 4 per 10 shares (including tax) and to increase capital by 3 shares for every 10 shares held[7]. - The company plans to expand its market presence and invest in new product development to sustain growth[60]. - The company aims to enhance its global production capacity to mitigate the impact of trade friction, particularly due to increased tariffs on imports from China[108]. - The company is committed to transforming its business model from OEM/ODM to OBM, leveraging its design and production capabilities to gain market share[102]. Employee Information - The total number of employees in the parent company is 1,325, while the total number of employees in major subsidiaries is 2,507, resulting in a combined total of 3,832 employees[194]. - The employee compensation structure consists of basic salary, performance pay, and welfare subsidies, with adjustments based on social economic levels and company performance expected in 2019[195]. - The company has not granted any stock incentives to directors and senior management during the reporting period[185].